Estrella Immunopharma Inc ESLA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors
Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Trading Information
- Previous Close Price
- $0.41
- Day Range
- $0.40–0.44
- 52-Week Range
- $0.24–3.01
- Bid/Ask
- $0.40 / $0.44
- Shares Outstanding
- 43.50M
- Market Cap
- $19.10M
- Volume/Avg
- 25,499 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.estrellabio.com
Valuation
Metric | ESLA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ESLA |
|---|---|
Quick Ratio | 0.04 |
Current Ratio | 0.20 |
Interest Coverage | — |
Quick Ratio
ESLA
Profitability
Metric | ESLA |
|---|---|
Return on Assets (Normalized) | −298.46% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ESLA
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|Tm%&qt | LOCK|C$^# | $138B | |||
| Moderna Inc MRNA | LOCK|MzMd#jT | LOCK|@%% | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|<S%f%b | LOCK|qCRX | $93B | |||
| argenx SE ADR ARGX | LOCK|%&Z#Nz | LOCK|BgV | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|jG>%g! | LOCK|D^g | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|KX!MpHq? | LOCK|^<#W | $30B | |||
| Incyte Corp INCY | LOCK|Lk<^!zk | LOCK|KM? | $24B | |||
| BioNTech SE ADR BNTX | LOCK|gf&>&? | LOCK|@jB | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|%v#?MxB | LOCK|M^?G | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|Kbbn$g | LOCK|YH | $15B |
United States